3626 results for «229»
3626 results
The right ventricle - Key determinant of tricuspid procedural planning and clinical outcomes
26 Nov 2024 – From PCR London Valves 2024
Looking to know more about the role of the right ventricle in the pathophysiology of tricuspid regurgitation? Don’t miss this video!
You’ll learn how to assess RV function and morphology with advanced imaging, uncover key parameters that predict outcomes, understand how RV remodeling impacts procedural success, and...
Multivalve disease: defining pathways for optimal assessment and treatment in the absence of good clinical evidence
26 Nov 2024 – From PCR London Valves 2024
Curious about managing multivalve disease in the absence of robust clinical evidence? This video is a must-watch!
You'll explore the latest strategies for assessing and treating this condition (including advanced multimodality investigations like echocardiography, magnetic resonance and cardiac catheterisation), and learn how to evaluate cardiopulmonary interactions and...
Featured research - Aortic valve (Part 11)
26 Nov 2024 – From PCR London Valves 2024
Explore the latest advancements in aortic valve research during this featured session, showcasing selected abstracts from the upcoming PCR London Valves 2024 conference. Delve into topics ranging from the long-term outcomes of bailout valve-in-valve TAVI, the performance of the Navitor THV in bicuspid aortic valves, novel...
Bioresorbable scaffolds versus permanent sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction: vascular healing outcomes from the MAGSTEMI trial
27 Dec 2020
The MAGSTEMI trial showed larger endothelium-independent vasodilatation with magnesium-based bioresorbable scaffolds (MgBRS) than with sirolimus-eluting stents (SES). However, restenosis was more frequent with MgBRS. The aims of this study were to compare the healing pattern between MgBRS and SES and to describe the main causes of...
Authors :
No go (again) for oral anticoagulation after TAVR: Results of the ADAPT-TAVR trial
04 Apr 2022
Francesco Costa analyses the results of ADAPT-TAVR, a prospective randomized trial on edoxaban vs dual antiplatelet therapy for valve thrombosis and cerebral thromboembolism after transcatheter aortic-valve replacement.
Author
TRILUMINATE pivotal: A landmark randomized clinical trial of transcatheter tricuspid valve edge-to-edge repair for tricuspid regurgitation
04 Mar 2023
Jonathan Curio and Alex Sticchi provide their take on this clinical trial which was presented by Paul Sorajja at the American College of Cardiology Scientific Session (ACC.23/WCC).
Author
Author
